performed molecular profiling of a 485‐glioma cohort using high‐sensitivity RT‐PCR, identifying PTPRZ1–MET (ZM) gene fusions in 14.3% of low‐grade glioma (LGG) and secondary GBM cases, which were undetected in primary GBM. This evidence concerns the gene MET and central nervous system cancer.